Understanding how a protein called TREM2 affects non-alcoholic steatohepatitis (NASH)
Dissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis.
['FUNDING_R01'] · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · NIH-11176076
This project explores how a protective protein called TREM2 works inside and outside liver cells to help prevent the progression of non-alcoholic steatohepatitis, a serious liver condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11176076 on ClinicalTrials.gov |
What this research studies
Non-alcoholic steatohepatitis (NASH) is a growing cause of liver disease, but we don't fully understand why some people with fatty liver get worse while others don't. This research focuses on a protein called TREM2, which appears to protect the liver from NASH and scarring. We are looking into how TREM2 works within liver cells and also how a soluble form of TREM2, found in the blood, might act as a protective signal. By understanding these mechanisms, we hope to uncover new ways to treat or prevent NASH.
Who could benefit from this research
Good fit: This foundational research is for patients with non-alcoholic fatty liver disease (NAFLD) or NASH who might benefit from future therapies developed from this understanding.
Not a fit: Patients without NAFLD or NASH are unlikely to directly benefit from this specific research, as it focuses on the mechanisms of this particular liver disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for NASH by targeting the TREM2 protein or its soluble form, potentially preventing liver damage and the need for liver transplants.
How similar studies have performed: While TREM2 is known to be involved in other inflammatory conditions, its specific role and therapeutic potential in NASH, especially regarding its soluble form, is a novel area of exploration.
Where this research is happening
LA JOLLA, UNITED STATES
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DHAR, DEBANJAN — SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- Study coordinator: DHAR, DEBANJAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.